Antaros Medical has done several additions to senior management recently with both Caroline Engvall, initially appointed Antaros Site Director in Uppsala, and Anders Strigen, Chief Financial Officer. Antaros former COO, Elisabeth Bolling-Sternevald has retired and Caroline Engvall is taking over this position.
Working on the global pharmaceutical arena, Antaros Medical is experiencing a rapid growth and is expanding in both the Mölndal and the Uppsala offices. The company is pioneering advanced imaging methodologies and tailor-made studies, using magnetic resonance imaging (MRI) and positron emission tomography (PET), for decision making in drug development with focus on the cardiometabolic (including NAFLD/NASH and chronic kidney disease), and oncology arena. Just recently, the company was also awarded with a Vinnova funding (Sweden’s Innovation Agency), to develop a unique imaging tool to aid better diagnosis and treatment of patients with chronic kidney disease.
“We have, since we started some 3,5 years ago, seen a very positive development of the company. Elisabeth has been absolute key on this journey. She has now decided to retire and Caroline is taking over the COO position. Anders and Caroline have brought key competences into the company and will be instrumental in a time of rapid growth. We are very happy to have them onboard.” says Johannes Hulthe, CEO at Antaros Medical.
Caroline Engvall, appointed Chief Operating Officer (COO), joined Antaros earlier this year as Site Director in Uppsala. Before that she held the COO position at PCG Clinical Services. She brings a long experience of clinical trials and drug development from several senior positions at both large and smaller CROs.
Anders Strigen has joined Antaros as Chief Financial Officer (CFO). He has over 25 years of experience in accounting&finance with key expertise in developing SMEs, company structures and managing rapid growth. Most recently, he held a position as CFO and member of the board at the CFO Group AB.